Loramyc is authorised in Switzerland
This article was originally published in Scrip
Executive Summary
BioAlliance Pharma's Loramyc (miconazole Lauriad) has been approved for marketing in Switzerland for the treatment of oropharyngeal candidiasis in immunocompromised patients, mainly cancer and AIDS patients with oral opportunistic infections.